iBio, Inc. IBIO
NASDAQ IBIO
$0.86 +0.04 (+4.31%)
As of: Oct 21, 2026 · 1:50 PM EDT

iBio (IBIO) Non-Current Debt (2020 - 2025)

Updated

iBio's Non-Current Debt was $64,000 in fiscal Q4 2025 (quarter ended Jun 30, 2025), down 91.6% from $766,000 a year earlier.

Analysis

iBio (IBIO) Non-Current Debt (2020 - 2025) Analysis & Trends

From fiscal Q4 2020 onward, iBio has reported Non-Current Debt for 11 quarters.

  • Non-Current Debt shows a five-year compound annual growth rate of -28.4% (FY2020 to FY2025).
  • In earlier fiscal years, Non-Current Debt was $766,000 in FY2024 (+217.8%) and $241,000 in FY2023.
  • The fiscal Q4 2025 figure marks the lowest quarterly Non-Current Debt since fiscal Q3 2021.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Eli Lilly 1,134.24 Bn 1,102.83 Bn 19.71 Bn 47.86 Bn
2 Johnson & Johnson 616.05 Bn 534.58 Bn 17.26 Bn 37.34 Bn
3 AbbVie 500.90 Bn 474.01 Bn 12.70 Bn 62.48 Bn
4 Merck 367.17 Bn 321.54 Bn 12.21 Bn 51.08 Bn
5 Novartis Ag 297.85 Bn 261.84 Bn 11.24 Bn 1.96 Bn
6 Astrazeneca 261.35 Bn 235.03 Bn 12.86 Bn 23.68 Bn
7 Amgen 235.77 Bn 191.17 Bn 7.24 Bn 51.86 Bn
8 Gilead Sciences 190.70 Bn 164.90 Bn 6.22 Bn 23.83 Bn
9 Pfizer 169.35 Bn 115.99 Bn 10.94 Bn 60.50 Bn
10 iBio 89.11 Mn -176.11 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 64,000.00
Dec 31, 2024 643,000.00
Sep 30, 2024 722,000.00
Jun 30, 2024 829,000.00
Jun 30, 2023 241,000.00
Mar 31, 2022 22.12 Mn
Dec 31, 2021 22.05 Mn
Mar 31, 2021 34,000.00
Dec 31, 2020 135,000.00
Sep 30, 2020 238,000.00
Jun 30, 2020 339,000.00
API Access

iBio Non-Current Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-debt&ticker=IBIO&period=max&api_key=YOUR_API_KEY